Faruqi and Faruqui, LLP Logo
Share this page

In re AndroGel Antitrust Litigation (II), 09-md-2084 (N.D. Ga.)


In the Androgel litigation, Faruqi & Faruqi, LLP represent a pharmaceutical wholesaler and a proposed class of direct purchasers of Abbott’s branded testosterone drug, AndroGel.  The case alleges that Abbott’s predecessor filed baseless patent litigation and entered a series of horizontal market allocation agreements with generic manufacturers Watson and Par/Paddock (also defendants in the case) to delay generic competition in violation of §§ 1 and 2 of the Sherman Act.  The class asserts that, as a result of the delay in generic competition, direct purchasers were overcharged by hundreds of millions of dollars.

Contact Counsel

Peter Kohn
Joseph T. Lukens
Faruqi & Faruqi, LLP
1617 JFK Boulevard, Suite 1550
Philadelphia, PA 19103
Tel: (215) 277-5770


Case Details


  • 02/03/2009

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.